(1554106) Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.

Sunday, October 8, 2023

9:45 AM – 9:55 AM EDT

Location: HCC, Ballroom ABC, Level 3

Primary Author; Presenting Author(s)

Andy C. Rawstron, PhD

Clinical Scientist
HMDS, Leeds Cancer Centre
Leeds, England, United Kingdom

Slides
Andy C. Rawstron, PhD

Clinical Scientist
HMDS, Leeds Cancer Centre
Leeds, England, United Kingdom

Slides

Co-Author(s)

NW

Nichola Webster, N/A

Leeds Institute of Medical Research at St James's, University of Leeds, United Kingdom
NW

Nichola Webster, N/A

Leeds Institute of Medical Research at St James's, University of Leeds, United Kingdom
DA

David Allsup, MD

Department Hematology, Hull University Teaching Hospitals NHS Trust
Hull, England, United Kingdom
DA

David Allsup, MD

Department Hematology, Hull University Teaching Hospitals NHS Trust
Hull, England, United Kingdom
SB

Sue Bell, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
SB

Sue Bell, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
AB

Adrian Bloor, MD

Christie Hospital NHS Trust
Manchester, United Kingdom
AB

Adrian Bloor, MD

Christie Hospital NHS Trust
Manchester, United Kingdom
DC

David Cairns, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
DC

David Cairns, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
AH

Anna Hockaday, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
AH

Anna Hockaday, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
SJ

Sharon Jackson, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
SJ

Sharon Jackson, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
SD

Surita Dalal, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds
St. James’s Institute of Oncology, United Kingdom
SD

Surita Dalal, PhD

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds
St. James’s Institute of Oncology, United Kingdom
Rd

Ruth de Tute, PhD

HMDS, Leeds Cancer Centre
Leeds, England, United Kingdom
Rd

Ruth de Tute, PhD

HMDS, Leeds Cancer Centre
Leeds, England, United Kingdom
NG

Natasha Greatorex, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
NG

Natasha Greatorex, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
RL

Rhiannon Lambkin, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
RL

Rhiannon Lambkin, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
AS

Anita Sarma, MB, ChB

HMDS, Leeds Cancer Centre
Leeds, England, United Kingdom
AS

Anita Sarma, MB, ChB

HMDS, Leeds Cancer Centre
Leeds, England, United Kingdom
DS

David Stones, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
DS

David Stones, N/A

Leeds CRUK CTU, Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom
AV

Abraham Varghese, MB BS, PhD

Clinical Haematology, Leeds Teaching Hospitals NHS Trust, United Kingdom
AV

Abraham Varghese, MB BS, PhD

Clinical Haematology, Leeds Teaching Hospitals NHS Trust, United Kingdom
Peter Hillmen, MB ChB, PhD

Professor of Experimental Haematology
Leeds Institute of Medical Research at St James's, University of Leeds
St. James University Hospital
Leeds, England, United Kingdom
Peter Hillmen, MB ChB, PhD

Professor of Experimental Haematology
Leeds Institute of Medical Research at St James's, University of Leeds
St. James University Hospital
Leeds, England, United Kingdom
Talha Munir, MBBS, PhD

Consultant Haematologist
Clinical Haematology, Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
Talha Munir, MBBS, PhD

Consultant Haematologist
Clinical Haematology, Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom

Disclosure(s):

Andy C. Rawstron, PhD: No relevant disclosure to display